April 4, 2013 7:31 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
pSivida Corp. (NASDAQ: PSDV), a specialty pharmaceutical company thatis a leader in the development of sustained release ophthalmic drugtreatments, today announced that it has signed a funded technology evaluationagreement with a leading global pharmaceutical company. The agreement willevaluate pSivida's proprietary Durasert™ and Tethadur™ technologies for thispharmaceutical company's select products in ophthalmology. The Duraserttechnology system delivers specific quantities of drugs directly to a targetsite in the body at controlled rates for predetermined periods of time rangingfrom weeks to months. Tethadur is pSivida's proprietary technology for thedelivery of proteins, peptides and antibodies.“We are extremely pleased to be working with another global pharmaceuticalcompany to apply our unique technologies to develop transformational productsin ophthalmology,” said Dr. Paul Ashton, pSivida president and CEO.pSivida has developed three of the four sustained release devices for retinaldiseases that have been approved in either the US or Europe, the most recentbeing ILUVIEN®, partnered with Alimera and approved in multiple EU countries.Independently, pSivida is developing an injectable, sustained release productto treat uveitis affecting the back of the eye (posterior uveitis) and aninjectable, bioerodible product to treat glaucoma and ocular hypertension incollaboration with Pfizer.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.